Johnson, T. S., Aguilera, D., Al-Basheer, A., Berrong, Z., Castellino, R. C., Eaton, B. R., Esiashvili, N., Foreman, N., Heger, I. M., Kennedy, E. P., Vahanian, N., Martin, W., Pacholczyk, R., Ring, E., Sadek, R. F., Smith, A., Shimoda, M., Macdonald, T. J., & Munn, D. H. (n.d.). 101P Results of the NLG2105 phase I trial using the IDO pathway inhibitor indoximod, in combination with radiation and chemotherapy, for children with newly diagnosed DIPG. Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100098459083.0x000033